News

Mucopolysaccharidosis Type I: Strategic Shift Underway As Gene Therapies &And Next-Gen Erts Challenge Market Dominance
DataM Intelligence | competitive Intelligence MPS I market evolution accelerates as gene therapies and BBB-penetrant ERTs emerge, challengi ...
The New York Times1mon
‘We Are the Most Rejected Generation’
“We are the most rejected generation,” he said. He’s right. He pointed to the admission rates at elite universities. By 1959, about half of American college applicants applied to just one schoo ...
PharmiWeb1mon
ViroCell manufactured a GMP lentiviral vector for UCL to accelerate research into prevention of relapse in childhood blood cancer
UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative ... support such prestigious research institutions as GOSH and UCL to bring next-generation CAR T-cells to ...
Business Wire1mon
ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer
Professor Amrolia selected ViroCell to manufacture the lentiviral vector for this novel ... institutions as GOSH and UCL to bring next-generation CAR T-cells to paediatric patients with relapsed ...
technologynetworks2mon
Level-Up Lentiviral Transduction Success With a Macroporous Sponge
Lentiviral transduction is a popular and powerful gene delivery method for downstream applications such as cell line generation, therapeutic model generation and CAR-T research. However, current ...
BioSpace3mon
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, ...
FierceBiotech6mon
Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing
To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.
The Scientist9mon
Scaling Up Lentiviral Vector Manufacturing
However, it is often difficult for scientists to ramp up the generation of these vectors to meet their ... from Thermo Fisher Scientific to learn how scientists have used their lentiviral production ...
Pharmaceutical Technology1y
Genezen to license CSL’s lentiviral vector production system
The advanced inducible technology produces lentiviral vectors (LVVs), which are vital for ... Genezen’s licensing of the Cytegrity system marks a substantial investment in next-generation technology ...